News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
Heidelberg Pharma dosed first patient in Phase I study of Amanitin-based ADC HDP-102 for Non-Hodgkin Lymphoma. ATAC technology targeting CD37. Promising data presented at AACR 2024 -
COMMUNIQUÉ DE PRESSE
Southern Energy Corp. Announces First Quarter 2025 Financial and Operating Results
Southern Energy Corp. reports Q1 2025 financial and operating results, highlighting increase in natural gas sales and premium over NYMEX HH benchmark. Company undergoes strategic financial actions and plans for near-term production growth -
-
-